This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022, with hepatocellular carcinoma (HCC) as the most common histological subtype, accounting for approximately 90% of liver cancers. Despite this, biomarkers that predict survival and therapeutic response to atezolizumab plus bevacizumab (Atezo/Bev), a type of systemic therapy in HCC management, have yet to be established in unresectable HCC, in which the tumor cannot be safely treated via surgical removal.
An Osaka Metropolitan University research team investigated the association between serum full-length glypican-3 (FL-GPC3) concentration and treatment outcomes in patients with unresectable HCC receiving Atezo/Bev.
The team looked at data from 102 patients treated with Atezo/Bev therapy for unresectable HCC at its institute during 2020–2025 and examined the association between baseline serum FL-GPC3 concentrations and the therapeutic effectiveness and survival outcomes.
Their investigation showed that the baseline serum FL-GPC3 concentration was lower in patients in whom disease control was achieved (10.8 vs. 26.7 pg/mL) and that the FL-GPC3-high group had shorter median progression-free survival (3.0 vs. 5.6 months) and overall survival (13.7 vs. 25.8 months) than the FL-GPC3-low group.
The results of this study show that baseline serum FL-GPC3 concentration was associated with treatment outcomes in patients with unresectable HCC receiving Atezo/Bev, suggesting its potential as a noninvasive biomarker for risk stratification. However, these findings still require validation in an independent, external cohort before clinical application can be considered.
Source link







